FDA's Approach to Regulation of Products of Nanotechnology

Science  20 Apr 2012:
Vol. 336, Issue 6079, pp. 299-300
DOI: 10.1126/science.1205441

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


The U.S. Food and Drug Administration (FDA) has long encountered the combination of promise, risk, and uncertainty that accompanies new technologies. This is equally true for nanotechnology, which engenders both excitement and concern owing to the rapidly evolving science and range of applications. The very changes in biological, chemical, and other properties that make some applications so exciting may also present new questions about how to predict, identify, measure, and monitor possibly harmful effects.